<DOC>
	<DOCNO>NCT01201018</DOCNO>
	<brief_summary>The study non randomize , open label , dose rise study cancer patient . Cancer treatment consist 2 different drug : Oshadi D Oshadi R administer orally . The study include two session : - A single dose period evaluate acute toxicity drug - Consecutive multiple increment dose escalation period drug determine long-term safety , anticancer activity .</brief_summary>
	<brief_title>Evaluation Safety Efficacy Oshadi D Oshadi R Cancer Treatment</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Histologically/ cytological proven solid tumor metastatic . Age &gt; 21 year old . ECOG Performance status &lt; 2 . Documented progressive metastatic disease accord RECIST criterion . At least one lesion within prior radiation field measurable per RECIST . Primary tumor must resect . Four week must elapse prior therapy . Patient recover CTCAE &lt; Grade 1 toxicity relate previous treatment ( except nonclinically significant AEs ) . Patient must adequate organ function . Sexually active fertile patient partner must agree use medically accept method contraception therapy 3 month last dose study drug . Female patient childbearing potential must negative pregnancy test screening . Patient must understand willing give write informed consent prior study procedure evaluation willing adhere study schedule requirement . Life expectancy &gt; 6 month . Uncontrolled Intercurrent illness history significant cardiac , renal , neurologic , metabolic , pulmonary , gastrointestinal , hematologic abnormality , chronic hepatic disease disease judgment investigator would interfere study confound result . Current history hematologic malignancy . Patient positive HIV serology screen . Female patient breastfeed positive pregnancy test screening time study . Radiation therapy &lt; 4 week prior screen . Patient receive type investigational agent &lt; 4 week prior screen . Metastatic brain meningeal disease . Patient prothrombin time/International Normalization Ration ( PT/INR ) partial thromboplastin time ( PTT ) test result &gt; 1.3 UNL . Significant swallow disorder . Small bowel surgery . Pelvic abdominal radiation . Preexisting mal absorption syndrome , irritable bowel syndrome clinical situation could affect oral absorption . Evidence concurrent ( &lt; 5 year ) second malignancy basal cell carcinoma skin cervical carcinoma situ . Mental disorder . Inability give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Tumor</keyword>
	<keyword>cancer</keyword>
	<keyword>metastasis</keyword>
</DOC>